当前位置: 首页 > 期刊 > 《内分泌学杂志》 > 2005年第12期 > 正文
编号:11411135
Involvement of Corticotropin-Releasing Hormone- and Interleukin (IL)-6
http://www.100md.com 《内分泌学杂志》
     Division of Cell Biology (D.C., Y.I.), Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan

    Department of Bioregulation (T.I.), Institute of Development and Aging Sciences, Nippon Medical School, Kanagawa 211-8533, Japan

    Third Department of Internal Medicine (T.S.), Hirosaki University School of Medicine, Hirosaki 036-8562, Japan

    Abstract

    IL-1/ and IL-6 are endogenous modulator of hypothalamo-pituitary-adrenal axis (HPAA) and are thought to play key roles in immune-neuroendocrine interactions during inflammation. Here, we show IL-1 induced a normal HPAA activation in IL-1/ knockout (KO) and IL-6 KO mice at 1 h; however, at 6 h HPAA activation was reduced relative to wild-type mice, indicating a role for endogenous IL-1/ and IL-6 in prolonged HPAA activation. We found that the induction of proopiomelanocortin (POMC) transcript in the anterior pituitary (AP) at 6 h in response to IL-1 was reduced in IL-1/ KO and IL-6 KO mice, as well as in CRH KO mice, suggesting IL-1/, IL-6, and CRH are all required for POMC induction. The induction of CRH transcript in the paraventricular nucleus at 6 h and plasma IL-6 levels, in response to IL-1, were reduced in IL-1/ KO mice. Because IL-1-induced activation of signal transducer and activator of transcription 3 in the AP was also suppressed in IL-6 KO mice, we suggest that plasma IL-6 is first induced by IL-1, and IL-6 activates signal transducer and activator of transcription 3 in the AP, leading to the induction of POMC in concert with CRH. Our results suggest a role for IL-1/ in the induction of POMC in the AP through the induction of two independent pathways, CRH and IL-6.

    Introduction

    ACTIVATION OF THE hypothalamic-pituitary-adrenal axis (HPAA) is a key host response to stress and inflammation. The resulting increase in adrenal glucocorticoid secretion prevents overshoot of immune/inflammatory responses, limiting the host defense response without the potentially deleterious effects of a hyperactive immune system (e.g. autoimmunity) (1). The secretion of glucocorticoids is stimulated by ACTH that is synthesized and secreted by the anterior pituitary (AP) gland. CRH is synthesized in the hypothalamic paraventricular nucleus (PVN) and secreted into the hypophysial portal circulation. In response to variety of stresses, secretion of ACTH and glucocorticoid occurs as a result of the increased activity of CRH-secreting neurons in the PVN (2). CRH signaling in the corticotroph increases both the transcription of the proopiomelanocortin (POMC) gene and the secretion of mature ACTH peptide (3). Induction of POMC gene expression by CRH is also observed in primary pituitary cultures and in the mouse corticotroph cell line AtT-20 (3, 4).

    Proinflammatory cytokines, released during systemic and localized inflammation, elicit a number of responses in the host, including fever and anorexia. The landmark studies by Besedovsky et al. and Blalock and colleagues (5, 6) indicated that IL-1/ and IL-6 could be the extrahypothalamic CRH released by injured tissue. Several reports have shown that IL-1/ stimulates HPAA mainly through the hypothalamus, and its action depends on CRH release (7). We have previously demonstrated that IL-1/ not only induce CRH release, but also induces expression of CRH in the PVN and POMC in the AP, which is a precursor of ACTH (8). Moreover, we showed the importance of IL-1/ in in vivo HPAA activation induced by turpentine; the corticosterone response in IL-1/ knockout (KO) mice was completely abolished 8 h after injection of turpentine, whereas it was normal 2 h after injection of turpentine (9). Although IL-1/ is known to be important for the activation of HPAA, the molecular mechanism by which these cytokines induce HPAA activation is poorly understood. IL-6 is another proinflammatory cytokine whose effects on the HPAA have been investigated extensively (10, 11, 12). Its levels in the circulation are increased during physical, psychological, and inflammatory stresses (2). Peripheral IL-6 administration in rodents induces ACTH and glucocorticoid secretion. Because peripheral injection of IL-1 or IL-1 induces plasma IL-6 (13), some of the actions of IL-1/ on the neuroendocrine network is thought to be mediated by the action of IL-6 (14, 15). Although a synergism between gp130 family cytokines and CRH on HPAA activation and POMC gene expression in vitro was reported by several studies (10, 16, 17), in vivo significance of each pathway remains to be elucidated.

    In this report, we have examined the HPAA response in CRH KO mice, IL-1/ KO mice, and IL-6 KO mice to elucidate the signaling cascade induced by periphery-administered IL-1. We demonstrate that IL-1 induces POMC in the AP, and both IL-1/ and IL-6 are involved in the prolonged activation of HPAA and the induction of POMC. It is suggested that IL-1 activates HPAA through the induction of CRH in the PVN and IL-6 in the plasma.

    Materials and Methods

    Reagents

    Recombinant murine IL-1 (rmIL-1) was obtained from Pepro Tech EC LTD (London, UK). The lyophilized protein was dissolved in 0.9% NaCl (saline) containing 0.1% BSA (A9306; Sigma, St. Louis, MO).

    Animals

    IL-1/ double-KO mice were produced as described (9) and IL-6 KO mice were kindly provided by Dr. Manfred Kopf (18). These mice were back-crossed to C57BL/6J mice for eight generations, and C57BL/6J (SLC Inc., Shizuoka, Japan) mice were used as controls. CRH KO mice generated by targeted mutation in embryonic stem cells were used in this study (19). Mice were housed individually after weaning at 4 wk of age, and age-matched (8–12 wk of age) male mice were used for each experiment. Mice were kept under specific pathogen-free conditions in an environmentally controlled clean room at the Center for Experimental Medicine, the Institute of Medical Science, the University of Tokyo. Mice were housed at an ambient temperature of 24 C and a daily cycle of 12 h light (0800–2000 h) and 12 h darkness. All experiments were carried out according to the institutional ethical guidelines for animal experiments and according to the safety guidelines for gene manipulation experiments.

    Hormone assays

    IL-1/ double-KO, IL-6 KO, CRH KO, and wild-type (WT) mice were injected with IL-1 (20 μg per kg of body weight, ip) or saline at 1000 h and killed 1, 3, or 6 h after administration. Mice were rapidly anesthetized with diethyl-ether, and blood samples were collected from the heart. Plasma corticosterone levels were determined by RIA (detection limit: 0.6 ng/ml; Amersham Biosciences, Buckinghamshire, UK). The intra- and interassay assay coefficients of variation were 5.0% and 5.9%, respectively. Plasma ACTH concentration was determined by immunoradiometric assay (detection limit: 5 pg/ml; Mitsubishi, Tokyo, Japan). The intra- and interassay assay coefficients of variation were 3.5% and 5.0%, respectively. Plasma IL-6 levels were measured by ELISA (detection limit: 10 ng/ml; PharMingen, San Diego, CA) according to the manufacturer’s instructions.

    In situ hybridization

    Mice were deeply anesthetized and perfused transcardially with 4% neutralized paraformaldehyde. Frozen sections (30 μm) were cut on a sliding microtome, mounted onto silane-coated slides (Matsunami, Tokyo, Japan), and air-dried. The hybridization protocol was similar to that previously described (20). Before hybridization, sections were dried overnight under vacuum, digested with proteinase K (10 μg/ml, 37 C, 15–20 min), acetylated, and dehydrated. After vacuum drying, 100 μl of the hybridization mixture (106 cpm/ml, with 10 mM dithiothreitol) was spotted onto each slide, sealed under a coverslip, and incubated at 65 C overnight. The coverslips were then removed and the slides were rinsed in 4x SSC [1x SSC = 15 mM trisodium citrate buffer (pH 7.0)/0.15 M NaCl] at room temperature. The sections were digested with ribonuclease A (20 μg/ml, 37 C, 30 min) and washed in 0.1x SSC for 30 min at 65 C. These sections were then exposed to double-sided x-ray film (XAR-5; Eastman Kodak, Rochester, NY) at 4 C for periods of 7–14 d (depending upon the nature of the probes used), dipped in NTB2 nuclear emulsion (1:1 with water) (Kodak), exposed for 14–30 d, and developed. The slides were counterstained with thionin. An adjoining series of sections were stained with thionin to provide better cytoarchitectonic definition for analysis. All samples from a single experiment were assayed simultaneously.

    Probe labeling

    A pGEM-4 plasmid containing rat CRH cDNA (1.2 kb, a gift from Dr. K. Mayo, Northwestern University, Chicago, IL) was linearized with HindIII. Mouse POMC cDNA (923 bp, a gift from Dr. Douglass, Vollum Institute for Advanced Biomedical Research, Oregon Health Sciences University, Portland, OR), subcloned into Psp65O, was linearized with HindIII. The EcoRI fragment of rat c-fos cDNA (2.0 kb, Dr. I. Verma, Salk Institute, San Diego, CA) was subcloned into p-Bluescript SK-I and linearized with BamHI. Radioactive antisense cRNA copies were synthesized by incubating 0.1 μg linearized plasmid with SP6 (Roche Molecular, Indianapolis, IN) for CRH and POMC probes or T7 (Roche Molecular) for c-fos probe, in a reaction mixture containing 6 mM MgCl2, 2 mM spermidine, 8 mM dithiothreitol, 25 mM ATP/GTP/CTP, 5 mM unlabeled uridine triphosphate, (-35S)-uridine triphosphate (370 MBr/ml, Amersham Biosciences), 1 U RNAsin (Promega, Madison, WI), 36 mM Tris (pH 7.5), for 60 min at 37 C. All probes were purified on resin columns (Nensorb 20; NEN Life Science Products, Wilmington, MA). The specific activity of each probe was approximately 1.0 x 108 cpm/μl.

    The densities of CRH and c-fos mRNA in the PVN or POMC mRNA in the AP were semiquantified from the film autoradiograms using an MCID image analysis system (Imaging Research, St. Catherines, Canada) (21). The levels obtained were converted to relative ODs (RODs) using the formula: ROD = log10 (256/levels). Using the mouse brain atlas of Paxinos and Watson (22) as an anatomical guide, we enclosed the area of the medial parvocellular PVN by a rectangle (300 x 520 μm), forming a fixed window. The ROD within the window was measured and the background was assessed by measuring the ROD when the window was placed over another area of the brain where no specific hybridization for CRH was detected. The OD of the PVN was measured bilaterally for each subject.

    Western blot analysis

    IL-6 KO and WT mice were injected with IL-1 (20 μg per kg of body weight, ip) at 1000 h and decapitated at 1, 3, or 6 h after administration. Whole cell lysate from the pituitary was prepared and separated on a 7.5% SDS-PAGE, transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA), probed with monoclonal antiphospho-STAT3 (signal transducer and activator of transcription 3) (Tyr705) antibodies (no. 9131; Cell Signaling, Beverly, MA), and visualized by ECL (RPN 2131; Amersham Biosciences). Blots were stripped and reprobed with the anti-STAT3 antibody (no. 9132; Cell Signaling).

    Statistical analysis

    All values were calculated as means ± SEM. Comparisons of two groups was analyzed by the Student’s t test; for the comparisons of more than two groups, one- or two-way ANOVA was performed followed by Fisher’s protected least significant difference, Dunnett’s or Tukey’s tests were used to analyze statistical differences in each group. In all analyses, a two-tailed probability of less than 5% (i.e. P < 0.05) was considered statistically significant, and significance was confirmed in at least two independent experiments.

    Results

    HPAA response to IL-1

    To elucidate the roles of CRH, IL-1/, or IL-6 in the activation of HPAA in response to exogenous IL-1, we injected recombinant murine IL-1 into CRH KO, IL-1/ KO, and IL-6 KO mice, respectively, and measured the plasma corticosterone, ACTH, and IL-6 levels. Firstly, we analyzed the time course of the HPAA activation after IL-1 stimulation. When IL-1 was administered to WT mice (20 μg/kg of body weight, ip), corticosterone levels (Fig. 1A) and ACTH levels (Fig. 1B) were significantly elevated at 1, 3, and 6 h after injection.

    To examine the effect of CRH deficiency on HPAA activation in response to IL-1 , we measured plasma corticosterone and plasma ACTH levels at 1 h after peripheral injection of IL-1 in CRH KO mice. CRH KO mice failed to induce corticosterone (Fig. 2A) and ACTH in the plasma (Fig. 2B), indicating that endogenous CRH is required for the activation of HPAA at 1 h.

    Because exogenously administered IL-1-induced endogenous IL-1 and IL-1 in the periphery as well as in the brain (9, 23, 24, 25), we next analyzed the role of these endogenously induced IL-1/ components in IL-1/ KO mice. We measured plasma corticosterone (Fig. 3, A and C) and plasma ACTH levels (Fig. 3, B and D) in IL-1/ KO mice at 1 and 6 h after ip injection of IL-1. IL-1/ KO mice showed similar corticosterone and ACTH levels to these of WT mice at 1 h after injection (Fig. 3, A and B), indicating that endogenous IL-1/ expression is not required for HPAA activation at 1 h. In contrast, IL-1/ KO mice showed reduced plasma corticosterone and ACTH levels at 6 h after injection (Fig. 3, C and D) relative to WT mice, suggesting that endogenous IL-1/ is required for a prolonged HPAA response at 6 h.

    It is well known that IL-1/ induces IL-6. Furthermore, it was suggested that IL-6 plays an important role in turpentine- or lipopolysaccharide (LPS)-induced HPAA activation (10, 11). Then we examined the effect of IL-6 deficiency on HPAA activation. Significant reduction of corticosterone and ACTH levels was observed in IL-6 KO mice at 6 h after injection (Fig. 3, C and D), whereas the levels of these hormones were not reduced at 1 h after injection consistently with a previous report (26) (Fig. 3, A and B). Consistently with previous observations, plasma IL-6 levels were significantly elevated upon IL-1 stimulation in WT mice (Fig. 4). However, plasma IL-6 levels were reduced in IL-1/ KO mice at 3 h compared with WT mice (Fig. 4), indicating that endogenous IL-1/ is also necessary for the induction of IL-6. These results indicate that endogenous IL-6 is required for the prolonged HPAA activation at 6 h but is not required for the HPAA response at 1 h.

    Induction of POMC in the AP in response to IL-1 in IL-1/ KO mice

    To know the reason for the requirement of endogenous IL-1/ and IL-6 in prolonged activation of the HPAA in response to IL-1, we analyzed the expression of POMC, the precursor of ACTH, in the AP. After ip administration of IL-1, POMC expression was significantly induced in the AP after 6 h, but not at 1 h, in WT mice, as examined by in situ hybridization (Fig. 5A). In contrast, POMC induction was not observed after IL-1 injection after 6 h in IL-1/ KO mice (Fig. 5B) and IL-6 KO mice (Fig. 5C). The suppression of POMC induction in IL-1/ KO mice was confirmed in another experiment using 6 mice (see supplemental Fig. 1, which is published as supplemental data on The Endocrine Society’s Journals Online web site at http://endo.endojournals.org). These results suggest a possibility that blunted induction of POMC is responsible for the reduced activation of the HPAA in IL-1/ KO and IL-6 KO mice. We found that IL-1 also failed to induce POMC expression at 6 h after injection in CRH KO mice (Fig. 5D).

    Induction of CRH in the PVN in response to IL-1 in IL-1/ KO and IL-6 KO mice

    Because POMC expression is dependent on the expression of CRH, we next analyzed the induction of CRH in the PVN in WT, IL-1/ KO, and IL-6 KO mice. CRH transcript was clearly induced in the PVN of both WT and IL-6 KO mice at 6 h after IL-1 injection (Fig. 5, E and G). However, the induction of CRH was not observed in IL-1/ KO mice (Fig. 5F). These results indicate that IL-1/, but not IL-6, is necessary for the induction of CRH in the PVN.

    Activation of STAT3 in the pituitary in response to IL-1 is dependent on IL-6

    Because IL-6 activates STAT3, and STAT3 is suggested to play an important role in the expression of POMC in the pituitary (27, 28), we next analyzed the activation of STAT3 in the pituitary. Activation of STAT3 was observed 1–3 h after injection of IL-1 in WT mice (Fig. 6A), whereas it was blunted at 1 h after injection of IL-1 in IL-6 KO mice, clearly correlated with the levels of IL-6 in the plasma (Fig. 6B). Low-level activations of STAT3 were observed at later time points (data not shown). These results indicate that activation of STAT3 in response to IL-1 depends on plasma IL-6.

    Discussion

    In this study, we have analyzed the HPAA activation mechanisms in response to peripheral injection of IL-1 and demonstrated that the HPAA activation mechanism at 6 h is different from that at 1 h after stimulation; the activation depends only on CRH, but not IL-/ or IL-6, at 1 h, whereas it depends on both IL-1/ and IL-6 expression at 6 h. We found that POMC was induced at 6 h in the AP in a IL-1/-, IL-6-, and CRH-dependent manner, although it was not induced at 1 h. In agreement with our observations, Melmed and colleagues (27, 28) suggested that two independent pathways, CRH and gp130-STAT3, are important for the regulation of POMC gene expression in the AP.

    We showed recently that, upon induction of fever by peripheral IL-1 injection, endogenous IL-1/ expression is not necessary and IL-1-induced PGE2 and IL-6 in the brain play important roles (25). However, it is not known whether endogenous IL-1/ expression is required for the HPAA activation or CRH neuron activation in the PVN (29). In this report, we showed that the endogenous expression of IL-1/ is not necessary for the activation of HPAA at 1 h after injection with IL-1. In contrast to the febrile response, however, an important role for endogenous IL-1/ was suggested in the prolonged activation of HPAA at 6 h. The difference between the febrile response may be explained by the fact that HPAA, in contrast to fever, is regulated at the level of the pituitary, which is considered to be the peripheral part of the neuroendocrine system.

    Several lines of studies, including ours, have demonstrated that a variety of stresses that induces IL-1/ in the brain (9, 30), such as hypertonic saline injection (31), insulin-induced hypoglycemia (32), foot shock stress (33), and restraint stress (34), as well as peripheral injection of IL-1 or , induces CRH transcripts in the PVN (8). Furthermore, it was demonstrated that intracerebroventricular infusion of IL-1Ra attenuates the corticosterone response 24 h after tail shock stress (35) and that continuous intracerebroventricular infusion of IL-1Ra completely prevents the rise of CRH mRNA in PVN observed 8 h after administration of LPS (36). These results suggest that IL-1/ in the brain plays an important role in the activation of HPAA by inducing CRH mRNA in the PVN. Consistently with this notion, induction of CRH by peripherally injected IL-1 was abolished in IL-1/ KO mice (Fig. 5F), indicating that endogenous brain IL-1/, which is induced by IL-1 is important for the induction of CRH. On the other hand, IL-1 induced CRH in IL-6 KO mice, consistently with our previous observation that IL-1/ is normally induced in the brain by the peripheral injection of IL-1 in IL-6 KO mice (25). These results indicate that endogenous expression of IL-1/, but not IL-6, is required for the induction of CRH in response to IL-1. It should be noted here that IL-1/ KO mice have normal responsiveness to exogenously administered IL-1 because the induction of c-fos in the PVN in response to IL-1 in IL-1/ KO mice was similar to that in WT mice (see supplemental Fig. 2).

    We found that STAT3 activation in the pituitary after administration of IL-1 correlated with the induction of POMC. It is still controversial whether or not IL-1/ directly acts on the pituitary (37, 38). On the other hand, it was suggested that IL-6 can directly stimulate the pituitary because IL-6 receptor is expressed on the pituitary, plasma corticosterone levels after bacterial LPS injection in IL-6 KO mice are significantly lower than in WT mice, and administration of IL-6 induces ACTH release (11). Consistently with this idea, we found that peripheral injections of IL-1 induced STAT3 activation in the pituitary, which was abolished in IL-6 KO mice (Fig. 6). Furthermore, we found that POMC expression in the AP was reduced in IL-6 KO mice (Fig. 5G). Thus, it was suggested that IL-1 -induced IL-6 directly induces POMC in the AP through activation of STAT3. Although it was reported that LIF expression in the AP is important for the induction of POMC in response to IL-1 (39), we could not detect significant change of LIF expression under our experimental conditions (data not shown).

    Consistently with our notion, Venihaki et al. (12) demonstrated that, upon turpentine injection, immunoneutralization of ACTH abolished corticosterone rise in CRH KO mice despite the concomitant very high circulating IL-6 levels, suggesting that ACTH, which is induced in the AP by circulating IL-6, is the major mediator for HPAA activation. However, because Bethin et al. (11) demonstrated that IL-6 receptor is expressed on the adrenal glands, it is possible that IL-6 directly activates adrenal glands to secrete corticosterone. Actually, we detected STAT3 activation in the adrenal glands of WT mice in response to IL-1 (Chida, D., Y. Iwakura, unpublished results). The direct effect of IL-6 on the adrenal glands may be examined in the absence of CRH, in which ACTH and POMC are not induced (12) (Fig. 5D). However, as the zona fasciculate of the adrenal gland of CRH KO mice is atrophic due to chronic CRH deficiency (19), the lack of corticosterone response to IL-1 in CRH KO mice does not necessarily mean that IL-1-induced IL-6 cannot induce corticosterone response in the adrenal gland. Direct effect of IL-6 on adrenal gland might be observed if CRH were acutely deficient or adrenal size of CRH KO mice was restored by previous CRH or ACTH administration (40). Analysis of ACTH receptor (melanocortin receptor type II) KO mice should be useful to discriminate whether the effect of IL-6 on the HPAA depends on ACTH activity or not (i.e. direct effects of IL-6 on the adrenal glands).

    Taken together, we demonstrated that endogenous IL-1/ induction is important for prolonged activation of HPAA in response to IL-1, and that IL-1 induces CRH in the PVN and also induces IL-6, both of which are independently important for the POMC induction in the AP.

    Acknowledgments

    We thank Dr. Manfred Kopf for IL-6 KO mice. We thank all the members of our laboratory for their kind discussion and help with animal care.

    Footnotes

    This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labor and Welfare of Japan.

    First Published Online September 1, 2005

    Abbreviations: AP, Anterior pituitary; HPAA, hypothalamic-pituitary-adrenal axis; KO, knockout; LPS, lipopolysaccharide; POMC, proopiomelanocortin; PVN, paraventricular nucleus; rm, recombinant murine; ROD, relative OD; STAT3, signal transducer and activator of transcription 3; WT, wild type.

    Accepted for publication August 15, 2005.

    References

    Munck A, Guyre PM, Holbrook NJ 1984 Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25–44

    Turnbull AV, Rivier CL 1999 Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79:1–71

    Lundblad JR, Roberts JL 1988 Regulation of proopiomelanocortin gene expression in pituitary. Endocr Rev 9:135–158

    Autelitano DJ, Lundblad JR, Blum M, Roberts JL 1989 Hormonal regulation of POMC gene expression. Annu Rev Physiol 51:715–726

    Besedovsky H, del Rey A, Sorkin E, Dinarello CA 1986 Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233:652–654

    Woloski BM, Smith EM, Meyer 3rd WJ, Fuller GM, Blalock JE 1985 Corticotropin-releasing activity of monokines. Science 230:1035–1037

    Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W 1987 Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 238:522–524

    Suda T, Tozawa F, Ushiyama T, Sumitomo T, Yamada M, Demura H 1990 Interleukin-1 stimulates corticotropin-releasing factor gene expression in rat hypothalamus. Endocrinology 126:1223–1228

    Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, Iwakura Y 1998 Production of mice deficient in genes for interleukin (IL)-1, IL-1, IL-1/, and IL-1 receptor antagonist shows that IL-1 is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187:1463–1475

    Turnbull AV, Prehar S, Kennedy AR, Little RA, Hopkins SJ 2003 Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. Endocrinology 144:1894–1906

    Bethin KE, Vogt SK, Muglia LJ 2000 Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 97:9317–9322

    Venihaki M, Dikkes P, Carrigan A, Karalis KP 2001 Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108:1159–1166

    Libert C, Brouckaert P, Shaw A, Fiers W 1990 Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice. Eur J Immunol 20:691–694

    Wilder RL 1995 Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 13:307–338

    Barton BE, Wilder RL 1997 IL-6: insights into novel biological activities. Clin Immunol Immunopathol 85:16–20

    Ray DW, Ren SG, Melmed S 1996 Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 97:1852–1859

    Mynard V, Latchoumanin O, Guignat L, Devin-Leclerc J, Bertagna X, Barre B, Fagart J, Coqueret O, Catelli MG 2004 Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorylated 3',5'-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Mol Endocrinol 18:2997–3010

    Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G 1994 Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339–342

    Muglia L, Jacobson L, Dikkes P, Majzoub JA 1995 Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 373:427–432

    Imaki T, Katsumata H, Konishi SI, Kasagi Y, Minami S 2003 Corticotropin-releasing factor type-1 receptor mRNA is not induced in mouse hypothalamus by either stress or osmotic stimulation. J Neuroendocrinol 15:916–924

    Paxinos G, Franklin BJ 2001 The mouse brain in stereotaxic coordinates. San Diego; Academic Press

    Imaki T, Wang XQ, Shibasaki T, Harada S, Chikada N, Takahashi C, Naruse M, Demura H 1995 Chlordiazepoxide attenuates stress-induced activation of neurons, corticotropin-releasing factor (CRF) gene transcription and CRF biosynthesis in the paraventricular nucleus (PVN). Brain Res Mol Brain Res 32:261–270

    Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG, Libby P 1987 Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139:1902–1910

    Warner SJ, Auger KR, Libby P 1987 Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol 139:1911–1917

    Kagiwada K, Chida D, Sakatani T, Asano M, Nambu A, Kakuta S, Iwakura Y 2004 Interleukin (IL)-6, but not IL-1, induction in the brain downstream of cyclooxygenase-2 is essential for the induction of febrile response against peripheral IL-1. Endocrinology 145:5044–5048

    Benigni F, Fantuzzi G, Sacco S, Sironi M, Pozzi P, Dinarello CA, Sipe JD, Poli V, Cappelletti M, Paonessa G, Pennica D, Panayotatos N, Ghezzi P 1996 Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 87:1851–1854

    Bousquet C, Melmed S 1999 Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. J Biol Chem 274:10723–10730

    Bousquet C, Zatelli MC, Melmed S 2000 Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest 106:1417–1425

    Ericsson A, Arias C, Sawchenko PE 1997 Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 17:7166–7179

    Rothwell NJ, Hopkins SJ, Hashimoto M, Lebel E, Vallieres L, Rivest S 1995 Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18:130–136

    Lightman SL, Young 3rd WS1988 Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J Physiol 403:511–523

    Suda T, Tozawa F, Yamada M, Ushiyama T, Tomori N, Sumitomo T, Nakagami Y, Demura H, Shizume K 1988 Insulin-induced hypoglycemia increases corticotropin-releasing factor messenger ribonucleic acid levels in rat hypothalamus. Endocrinology 123:1371–1375

    Imaki T, Nahan JL, Rivier C, Sawchenko PE, Vale W 1991 Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress. J Neurosci 11:585–599

    Imaki T, Xiao-Quan W, Shibasaki T, Yamada K, Harada S, Chikada N, Naruse M, Demura H 1995 Stress-induced activation of neuronal activity and corticotropin-releasing factor gene expression in the paraventricular nucleus is modulated by glucocorticoids in rats. J Clin Invest 96:231–238

    Johnson JD, O’Connor KA, Watkins LR, Maier SF 2004 The role of IL-1 in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neuroscience 127:569–577

    Kakucska I, Qi Y, Clark BD, Lechan RM 1993 Endotoxin-induced corticotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is mediated centrally by interleukin-1. Endocrinology 133:815–821

    Suda T, Tozawa F, Ushiyama T, Tomori N, Sumitomo T, Nakagami Y, Yamada M, Demura H, Shizume K 1989 Effects of protein kinase-C-related adrenocorticotropin secretagogues and interleukin-1 on proopiomelanocortin gene expression in rat anterior pituitary cells. Endocrinology 124:1444–1449

    Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG 1987 Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238:519–521

    Auernhammer CJ, Chesnokova V, Melmed S 1998 Leukemia inhibitory factor modulates interleukin-1-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 139:2201–2208

    Muglia LJ, Jacobson L, Weninger SC, Luedke CE, Bae DS, Jeong KH, Majzoub JA 1997 Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest 99:2923–2929(Dai Chida, Toshihiro Imaki, Toshihiro Su)